Eli Lilly, Novo Nordisk's Historic GLP-1 Pricing Deals

Eli Lilly and Novo Nordisk have agreed to reduce US prices for their key GLP-1 drugs, including Ozempic, Wegovy, Mounjaro, and Zepbound, to expand Medicare/Medicaid access. This strategic pricing deal is anticipated to boost Novo Nordisk's long-term revenue by increasing accessibility and mitigating compounded competition, despite recent stock volatility, though it is rated a 'Risky Buy'. Eli Lilly, leveraging strong US manufacturing and blockbuster tirzepatide sales, is positioned for continued growth and a potential $1 trillion market cap, presenting a more straightforward investment case.

Analysis

Eli Lilly and Novo Nordisk have strategically agreed to reduce US prices for their key GLP-1 drugs, including Ozempic, Wegovy, Mounjaro, and Zepbound. This move aims to expand Medicare/Medicaid access, which is expected to boost long-term revenue by increasing market penetration and mitigating competition from compounded alternatives. The general sentiment for this development is moderately positive (0.55), with an optimistic tone.

Novo Nordisk's stock experienced a sharp drop in 2025, yet the new pricing deal is projected to enhance long-term revenue by increasing drug accessibility and eliminating compounded competition. NVO is currently rated a "Risky Buy" with significant upside potential, contingent on resolving operational issues. The per-ticker sentiment for NVO is 0.5, indicating a neutral-to-slightly positive outlook despite the "Risky Buy" rating.

Eli Lilly, conversely, maintains a strong position due to its robust US manufacturing presence and blockbuster tirzepatide sales. These factors are expected to drive continued growth, potentially leading to a $1 trillion market capitalization. LLY stock presents a more straightforward, lower-risk investment case, reflected in its higher per-ticker sentiment of 0.8.

This strategic pricing adjustment reflects a proactive approach by both pharmaceutical giants to secure market share in the rapidly expanding GLP-1 segment. While NVO faces operational hurdles, LLY appears to be on a clearer growth trajectory, leveraging its existing strengths. The overall market impact score is 0.65, suggesting a notable positive influence from these developments.

Key Decisions for Investors

• Investors should monitor Novo Nordisk's operational improvements closely, as resolving these issues is critical for realizing the "Risky Buy" upside potential following the new pricing deal.
• Consider Eli Lilly as a relatively lower-risk investment in the GLP-1 sector, given its strong manufacturing base and established tirzepatide sales, which position it for continued growth and potential market cap expansion.
• Evaluate the long-term revenue impact of expanded Medicare/Medicaid access for both companies, as this strategic pricing move aims to secure market share and mitigate compounded competition.